» Articles » PMID: 30903319

Controlling Metastatic Cancer: the Role of Phytochemicals in Cell Signaling

Overview
Specialty Oncology
Date 2019 Mar 24
PMID 30903319
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Cancer is a serious health issue and a leading cause of death worldwide. Most of the cancer patients (approximately 90%) do not die from the consequences of the primary tumor development, but due to a heavily treatable metastatic invasion. During the lengthy multistep process of carcinogenesis, there are a lot of opportunities available to reverse or slow down the tissue invasion or the process of tumor metastasis formation.

Results: Current research has brought many promising results from anti-metastatic experimental studies, and has shown that chemoprevention by natural or semisynthetic phytochemicals with plethora of biological activities could be one of the potentially effective options in the fight against this problem. However, there is a lack of clinical trials to confirm these findings. In this review, we focused on summarization and discussion of the general features of metastatic cancer, and recent preclinical and clinical studies dealing with anti-metastatic potential of various plant-derived compounds.

Conclusions: Based on our findings, we can conclude and confirm our hypothesis that phytochemicals with pleiotropic anticancer effects can be very useful in retarding and/or reversing the metastasis process, and can also be used to prevent tissue invasion and metastases. But, further studies in this area are certainly necessary and desirable.

Citing Articles

Ugonin inhibits chondrosarcoma metastasis through suppressing cathepsin V via promoting miR-4799-5p expression.

Tran N, Chang T, Chi N, Lai K, Chen H, Fong Y Int J Biol Sci. 2025; 21(3):1144-1157.

PMID: 39897041 PMC: 11781170. DOI: 10.7150/ijbs.106827.


Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.

Hashim G, Shahgolzari M, Hefferon K, Yavari A, Venkataraman S Bioengineering (Basel). 2025; 12(1).

PMID: 39851281 PMC: 11759177. DOI: 10.3390/bioengineering12010007.


A Network Pharmacology Identified Metastasis Target for Oral Squamous Cell Carcinoma Originating from Breast Cancer with a Potential Inhibitor from .

Alqarni A, Hosmani J, Alassiri S, A Alqahtani A, Assiri H Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458948 PMC: 11510435. DOI: 10.3390/ph17101309.


L. fruit peels show anti-cancer effects in preclinical models of breast carcinoma: The perspectives in the chemoprevention and therapy modulation.

Dvorska D, Mazurakova A, Lackova L, Sebova D, Kajo K, Samec M Front Oncol. 2024; 14:1463656.

PMID: 39435289 PMC: 11491292. DOI: 10.3389/fonc.2024.1463656.


Mechanisms of action of for prostate cancer treatment: network pharmacology, molecular docking and experimental validation.

Li W, Jiang H, Zhang W, Sun Q, Zhang Q, Xu J Front Pharmacol. 2024; 15:1407525.

PMID: 39318781 PMC: 11420528. DOI: 10.3389/fphar.2024.1407525.


References
1.
Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo J . Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001; 61(14):5491-8. View

2.
Miller K, Chap L, Holmes F, Cobleigh M, Marcom P, Fehrenbacher L . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23(4):792-9. DOI: 10.1200/JCO.2005.05.098. View

3.
Ramaswamy B, Elias A, Kelbick N, Dodley A, Morrow M, Hauger M . Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006; 12(10):3124-9. DOI: 10.1158/1078-0432.CCR-05-2603. View

4.
Chaffer C, Brennan J, Slavin J, Blick T, Thompson E, Williams E . Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006; 66(23):11271-8. DOI: 10.1158/0008-5472.CAN-06-2044. View

5.
Nishida N, Yano H, Nishida T, Kamura T, Kojiro M . Angiogenesis in cancer. Vasc Health Risk Manag. 2007; 2(3):213-9. PMC: 1993983. DOI: 10.2147/vhrm.2006.2.3.213. View